Therapy Areas: Inflammatory Diseases
Abbott receives approval for HUMIRA from the United States Food and Drug Administration
1 October 2012 - Abbott (NYSE: ABT), a health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and...
UCB, Astellas ink collaboration for rheumatoid arthritis drug Cimzia
1 February 2012 - Belgian UCB SA (EBR:UCB) said on Wednesday it had sealed an agreement with Japanese Astellas (TSE:4503) to collaborate in the development and marketing of UCB's rheumatoid arthr...
Biomerica releases new test to detect patients at risk of developing serious side effects from thiopurine drugs
1 February 2012 - US biomedical company Biomerica Inc (OTCBB:BMRA) said on Tuesday it had released a new patented Thiopurine methyltransferase (TPMT) test to identify individuals who are at risk of de...
Orexo ends collaboration with Janssen
31 January 2012 - Sweden's Orexo AB (STO:ORX) and Janssen Pharmaceuticals Inc, a company of US Johnson & Johnson (NYSE:JNJ), announced their decision to end their research collaboration and l...
EMA's committee recommends Remicade (infliximab) for ulcerative colitis in children
23 January 2012 - Merck & Co Inc (NYSE:MRK) said on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommend...
Bridge Bioresearch gets US patent for CD14 molecule
20 January 2012 - British drug developer Bridge Bioresearch Plc, or BBR, today said it had received US patent for its CD14 molecule for the treatment of Type 2 diabetes, obesity, atheroschlerosis and ...